Tuberculosis and Respiratory Diseases

The Korean Academy of Tuberculosis and Respiratory Diseases (대한결핵및호흡기학회)
권호 표지
DOI QR코드

DOI QR Code

Is the Combination of ICS and LABA, a Therapeutic Option for COPD, Fading Away?

  • Oh, Yeon-Mok (Department of Pulmonary and Critical Care Medicine, Asan Medical Center, University of Ulsan College of Medicine)
  • Received : 2016.12.20
  • Accepted : 2016.12.23
  • Published : 2017.01.31
Download PDF
⟨ Previous Next ⟩

Abstract

Keywords

References

  1. Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007;356:775-89. https://doi.org/10.1056/NEJMoa063070
  2. Wedzicha JA, Banerji D, Chapman KR, Vestbo J, Roche N, Ayers RT, et al. Indacaterol-glycopyrronium versus salmeterol-fluticasone for COPD. N Engl J Med 2016;374:2222-34. https://doi.org/10.1056/NEJMoa1516385
  3. Wedzicha JA, Calverley PM, Seemungal TA, Hagan G, Ansari Z, Stockley RA, et al. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med 2008;177:19-26. https://doi.org/10.1164/rccm.200707-973OC
  4. Beeh KM. The role of bronchodilators in preventing exacerbations of chronic obstructive pulmonary disease. Tuberc Respir Dis 2016;79:241-7. https://doi.org/10.4046/trd.2016.79.4.241
  5. GOLD 2017 Global strategy for the diagnosis, management and prevention of COPD [Internet]. Global Initiative for Chronic Obstructive Lung Disease; 2016 [cited 2016 Dec 21]. Available from: http://goldcopd.org/gold-2017-global-strategy-diagnosis-management-prevention-copd/.
  6. Kew KM, Seniukovich A. Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2014;(3):CD010115.
  7. Gershon AS, Campitelli MA, Croxford R, Stanbrook MB, To T, Upshur R, et al. Combination long-acting beta-agonists and inhaled corticosteroids compared with long-acting betaagonists alone in older adults with chronic obstructive pulmonary disease. JAMA 2014;312:1114-21. https://doi.org/10.1001/jama.2014.11432

Cited by

  1. Risk for pneumonia requiring hospitalization or emergency room visit according to delivery device for inhaled corticosteroid/long-acting beta-agonist in patients with chronic airway diseases as real-w vol.9, pp.1, 2017, https://doi.org/10.1038/s41598-019-48355-2